Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

PX’Therapeutics S.A.. (6/14/13). "Press Release: PX'Therapeutics Announces Appointment of New CEO".

Organisations Organisation PX’Therapeutics S.A.
  Group Aguettant (Group)
  Organisation 2 Laboratoire Aguettant S.A.S.
  Today Aguettant (Group)
  Group Aguettant (Group)
Products Product contract manufacturing (biologicals)
  Product 2 pharmaceutical
  Index term 2 PX'Therapeutics–Aguettant: investment, 201210 acquisition of majority stake by Aguettant Biotech
Persons Person Rougemond, Eric (Aguettant 201302– CEO)
  Person 2 Rousselle, Tristan (Protein’eXpert 200011–201306 CEO + Co-Founder LEFT 6/13 before Genome Express)
     


PX'Therapeutics announces the appointment of Dr. Eric Rougemond as Chief Executive Officer with immediate effect. He replaces Mr. Tristan Rousselle co-founder and Chief Executive Officer of PX'Therapeutics since November 2000.

Eric Rougemond, CEO of Aguettant Group since February 2013, will manage the CMO located in Grenoble (France), expert in engineering and biomanufacturing of recombinant proteins.

He has an extensive experience in managing international projects and P&Ls in specialty pharmas and biotech. This change follows the acquisition of PX'Therapeutics by Aguettant and the plans of Tristan Rousselle to set up new projects.

"Eric wants to thank Tristan for his instrumental role in PX'Therapeutics and wishes him a lot of successes in his new projects".

Aguettant and PX'Therapeutics clearly reaffirm their willingness to further strengthen synergies between both entities and to develop the Biotech hub of Aguettant Group.


About PX'Therapeutics : Biotechnology company
Areas of expertise : Engineering and development of valuable and complex recombinant proteins, GMP clinical manufacturing services, antibody humanization.
More information : www.px-therapeutics.com

About Aguettant : Independent family owned pharmaceutical company - Turnover 90 M€
Mission : Development, manufacturing, marketing and sales of injectable medicine mainly for the hospital market.
Therapeutic areas :
- Anesthesia - intensive care
- Parenteral micronutrients
- Neurology
Current project : Launch of a new unit of R&D and manufacturing which will boost its capacity of innovation and international development.
More information : www.aguettant.com


Contacts : eric.rougemond@aguettant.fr - ericrougemond@px-therapeutics.com
coralie.mannino@aguettant.fr


PX'Therapeutics
BHT BÂT 52 B - 7 parvis Louis Néel BP50 - 38040 Grenoble cedex 9 - FRANCE
Tel : 0 (33) 438 02 36 50 - Fax : 0 (33) 476 96 10 38

AGUETTANT Santé
1 rue Alexander Fleming - BP 7144 - 69353 Lyon Cedex 07 - Franc e
Tel + 33 (0) 4 78 61 51 41 - Fax + 33 (0) 4 78 61 09 35

   
Record changed: 2016-01-10

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Aguettant (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top